Overview

Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy

Status:
Terminated

Trial end date:
2017-09-30

Target enrollment:

Participant gender:

Summary

This clinical trial studies how well fosaprepitant dimeglumine and granisetron transdermal system work in preventing nausea and vomiting in patients with breast cancer undergoing chemotherapy. Antiemetic drugs may help lessen or prevent nausea and vomiting in patients treated with chemotherapy

Phase:

Phase 1

Details

Lead Sponsor:

University of Southern California

Collaborator:

National Cancer Institute (NCI)

Treatments:

Aprepitant
Fosaprepitant
Granisetron